Danielle Ternyila | Authors

Articles

FDA Grants Priority Review to Adjuvant Nivolumab for Resected Esophageal/GEJ Cancer

January 20, 2021

The FDA accepted a supplemental Biologics License Application for nivolumab as adjuvant treatment of patients with resected esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiation therapy and granted it Priority Review.